Johnson & Johnson Surges to 10th in Trading Volume Despite Stock Price Drop

On April 1, 2025, Johnson & Johnson (JNJ) experienced a significant trading day with a turnover of $3.623 billion, marking a 75.07% increase from the previous day. This surge placed JNJ as the 10th highest traded stock of the day. However, the stock price of JNJ declined by 7.59%.

Johnson & Johnson has announced that it will complete its acquisition of Intra-Cellular Therapies around April 2, 2025. This acquisition is expected to boost JNJ's 2025 sales growth by 0.8%, adding approximately $0.7 billion in incremental sales. The transaction is anticipated to dilute adjusted earnings per share (EPS) by $0.25 in 2025, an improvement from the previously estimated $0.30-$0.35 dilution. For 2026, earnings dilution is expected to decrease to $0.21 per share as operational accretion partially offsets annualized financing costs. JNJ will incorporate these estimates into its full-year 2025 financial outlook during the first quarter results announcement on April 15, 2025. Following the acquisition, Intra-Cellular Therapies will delist from NASDAQ.